

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2 Exhibit)

February 2005

BUDGET ACTIVITY

4 - Advanced Component Development and Prototypes

PE NUMBER AND TITLE

0603□0□A - Medical Systems - Adv Dev

COST (In Thousands)	FY 2004 Actual	FY 2005 Estimate	FY 2006 Estimate	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	Cost to Complete	Total Cost
Total Program Element (PE) Cost	12715	20286	10134	11842	13277	22639	22306	11421	Continuing	Continuing
808 DOD DRUG & VACC AD	5207	5253	5343	5405	6365	6063	5991	5913	0	50424
811 MIL HIV VAC&DRUG DEV	128	0	146	150	153	154	149	148	Continuing	Continuing
836 COMBAT MEDICAL MATL AD	3969	7325	3694	3753	4825	14556	14386	3582	0	59910
837 SOLDIER SYS PROT-AD	1063	712	951	2534	1934	1866	1780	1778	0	13467
MD4 FUTURE MEDICAL SHELTER	0	5080	0	0	0	0	0	0	0	1338
MD7 AUTOMATED LABORATORIES FOR BIODEFENSE (CA)	2348	0	0	0	0	0	0	0	0	2473
MD8 ELECTROSOMOTIC PAIN THERAPY SYSTEM (CA)	0	958	0	0	0	0	0	0	0	958
MD9 PORTABLE OXYGEN GENERATOR (CA)	0	958	0	0	0	0	0	0	0	958

A. Mission Description and Budget Item Justification: This program element (PE) funds advanced development of medical materiel within the early-on system integration in the System Development and Demonstration portion of the acquisition life cycle. The PE supports transition of Science and Technology initiatives, prototypes, or candidate technologies into the first scale-up, integrated models for initial technical and operational test and evaluation, when applicable. These programs are aligned to meet Future Force (F2) requirements stressed within the concept documents and organizational structures. The PE provides funding for early Phase 1 and 2, U.S. Food and Drug Administration (FDA) regulated, human clinical trials. The major enablers supported by this PE are:

Infectious disease vaccines and preventive drugs that will reduce the risk of service members contracting debilitating or fatal diseases, especially with the growing potential which urban warfare delivers. Disease and non-battle injuries (DNBI) are the largest contributors to the level 3 medical footprint, and significant reductions of the medical footprint in theater is achieved by reducing the number of DNBI affected soldiers. More importantly, reduced patient evacuations within F2 units is a force multiplier, because timely replacement of these uniquely skilled and combat tested soldiers will be nearly impossible.

Combat Casualty Care devices and biologics, with two major focuses: enhance forward care at the first responder level and reduce the footprint of medical organizations for greater mobility and easier sustainment. The F2 concept places soldiers into a more austere environment with lengthened evacuation times (both arrival and transit). Supporting medics and first responders require greater lifesaving and extended stabilization capability to save lives. Reduction in weight, cube, and sustainment requirements, allows medical units to increase mobility and maintain contact with their

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2 Exhibit)

February 2005

BUDGET ACTIVITY

4 - Advanced Component Development and Prototypes

PE NUMBER AND TITLE

0603□0□A - Medical Systems - Adv Dev

supported Units of Action.

Soldier Performance Enhancers in the form of drugs or diagnostics that allow commanders to increase soldiers' cognitive awareness and stamina. Enhancers have a direct relationship to increased soldier capabilities and a potential to reduce casualties.

Military HIV Vaccine and Drug Development – funds militarily relevant HIV medical countermeasures. These include advanced component development of sufficient candidate vaccines and drugs to permit large-scale field testing and education/training materials.

This program is managed by the U.S. Army Medical Research and Materiel Command.

<u>B. Program Change Summary</u>	FY 2005	FY 2006	FY 2007
Previous President's Budget (FY 2005)	10258	10458	11929
Current Budget (FY 2006/2007 PB)	20286	10134	11842
Total Adjustments	10028	-324	-87
Net of Program/Database Changes			
Congressional Program Reductions	-299		
Congressional Rescissions			
Congressional Increases	10800		
Reprogrammings			
SBIR/STTR Transfer	-473		
Adjustments to Budget Years		-324	-87

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)

February 2005

BUDGET ACTIVITY

4 - Advanced Component Development and Prototypes

PE NUMBER AND TITLE

0603□0□A - Medical Systems - Adv Dev

PROJECT

□0□

COST (In Thousands)	FY 2004 Actual	FY 2005 Estimate	FY 2006 Estimate	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	Cost to Complete	Total Cost
808 DOD DRUG & VACC AD	5207	5253	5343	5405	6365	6063	5991	5913	0	50424

A. Mission Description and Budget Item Justification: This project funds technical development of candidate medical countermeasures for infectious diseases that occur within militarily relevant areas of the world. Current products fall within three major areas: vaccines, drugs, and diagnostic kits. The funds support Phase 1 and 2 human clinical trials for safety, determining the genetics of the immune system, and small-scale efficacy testing. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis if contracted, and speeding recovery once diagnosed. These trials are required to meet U.S. Food and Drug Administration (FDA) regulatory approval guidance, a mandatory obligation for all military products placed into the hands of medical providers or service members. Priority is based upon four major factors: (1) the extent of the disease within the Combatant Commands' theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production).

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)

February 2005

BUDGET ACTIVITY

4 - Advanced Component Development and Prototypes

PE NUMBER AND TITLE

0603□0□A - Medical Systems - Adv Dev

PROJECT

□0□

Accomplishments/Planned Program

Reviews, evaluations, and trials of malarial/anti-malarial vaccines, drugs, and diagnostics: In FY04, initiated true negative (CONUS) and completed finger stick (OCONUS) trials with the Malaria Rapid Diagnostic Device (MRDD); initiated a Phase 1/2 safety and efficacy trial of the Recombinant P falciparum malaria vaccine in U.S. volunteers. In FY05, conduct a Milestone C IPR to transition MRDD to Full-Rate Production and Deployment, resulting in fielding of state-of-the-art malaria diagnostic capability for military physicians; conduct a Critical Design Review to determine if the Recombinant P falciparum malaria vaccine should continue to advanced Phase 2/3 testing OCONUS. In FY06, initiate Phase 2/3 testing of Recombinant P falciparum malaria vaccine OCONUS in Kenya. In FY07, continue Recombinant P falciparum malaria vaccine trials OCONUS; transition the anti-malarial drug, Artesunate (for treatment of severe and complicated malaria) to System Development and Demonstration (Milestone B) and initiate Phase 2b efficacy studies.

FY 2004 FY 2005 FY 2006 FY 2007

1613 2596 3243 5405

Trials, evaluations, and reviews for grouped infectious disease vaccines and drugs (Hepatitis E and Leishmania). In FY04, completed evaluation of the results of the multiyear Phase 2 trial of the Hepatitis E Vaccine conducted in Nepal; completed the Phase 2 field trial of the current formulation of the Paramomycin/Gentamicin Topical Antileishmanial Cream and initiated a solicitation for a contract for production and continued testing of the product.

400 0 0 0

In FY04, initiated a phase 1/2 study of the Dengue Tetravalent Vaccine (DTVV) in Thailand; completed production and testing of the master seeds for the DTVV. In FY05, complete Phase 2 testing of the DTVV in Thailand and analyze results. In FY06, conduct a Critical Design Review and transition the DTVV to full scale field-testing.

3097 2657 2100 0

Small Business Innovative Research/Small Business Technology Transfer Programs

97 0 0 0

Totals

5207 5253 5343 5405

B. Other Program Funding Summary: Not applicable for this item.

C. Acquisition Strategy: Test and evaluate in-house and commercially developed products in extensive government-managed clinical trials to gather data required for FDA licensure and Environmental Protection Agency registration.

ARMY RDT&E COST ANALYSIS(R3)									February 2005				
BUDGET ACTIVITY					PE NUMBER AND TITLE					PROJECT			
4 - Advanced Component Development and Prototypes					060300A - Medical Systems - Adv Dev					00			
I. Product Development	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract	
a . No product/contract costs greater than \$1M individually			3850	473		480		486		Continue	5289	Continue	
Subtotal:			3850	473		480		486		Continue	5289	Continue	
II. Support Cost	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract	
a . No product/contract costs greater than \$1M individually			698	158		160		162		Continue	1178	Continue	
Subtotal:			698	158		160		162		Continue	1178	Continue	

ARMY RDT&E COST ANALYSIS(R3)									February 2005				
BUDGET ACTIVITY					PE NUMBER AND TITLE					PROJECT			
4 - Advanced Component Development and Prototypes					060300A - Medical Systems - Adv Dev					00			
III. Test and Evaluation	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract	
a . No product/contract costs greater than \$1M individually			17120	3782		3849		3892		Continue	28643	Continue	
Subtotal:			17120	3782		3849		3892		Continue	28643	Continue	
IV. Management Services	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract	
a . No product/contract costs greater than \$1M individually			3710	840		854		865		Continue	6269	0	
Subtotal:			3710	840		854		865		Continue	6269	0	
Project Total Cost:			25378	5253		5343		5405		Continue	41379	Continue	

Schedule Profile (R4 Exhibit)

February 2005

BUDGET ACTIVITY

4 - Advanced Component Development and Prototypes

PE NUMBER AND TITLE

060300A - Medical Systems - Adv Dev

PROJECT

00

Event Name	FY 04				FY 05				FY 06				FY 07				FY 08				FY 09				FY 10				FY 11			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4				
(1) PBD, (2) DDR Leishmania Skin Test					1		2																									
(3) MS C Leishmania Skin Test																3																
(4) SDD Paromomycin/Gentamicin					4																											
(5) CDR, (6) DRR RTS, S improved malaria vaccine					5		6																									
(7) MS C RTS, S improved malaria vaccine																				7												
(8) MS C Malaria Rapid Diag Device									8																							
(9) CDR, (10) MS C Dengue Tetra Vaccine																				10												
(11) CDR, (12) DRR Hepatitis E Vaccine					11		12																									
(13) MS C Hepatitis A Vaccine													13																			

Schedule Detail (R4a Exhibit)						February 2005		
BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes				PE NUMBER AND TITLE 060300A - Medical Systems - Adv Dev			PROJECT 00	
<u>Schedule Detail</u>	FY 2004	FY 2005	FY 2006	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011
Leishmania Skin Test		1Q						
Paromomycin/Gentamicin	3-4Q							
RTS,S/improved adjuvant (P. falciparum) malaria vaccine		1Q						
Malaria Rapid Diagnostic Device (Milestone C)		3Q						
Dengue Tetravalent Vaccine (Critical Design Review)		3Q						
Hepatitis E Vaccine	3-4Q							
Dengue tetravalent vaccine (Critical Design Review)		3Q						

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)

February 2005

BUDGET ACTIVITY

4 - Advanced Component Development and Prototypes

PE NUMBER AND TITLE

0603□0□A - Medical Systems - Adv Dev

PROJECT

□36

COST (In Thousands)	FY 2004 Actual	FY 2005 Estimate	FY 2006 Estimate	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	Cost to Complete	Total Cost
836 COMBAT MEDICAL MATL AD	3969	7325	3694	3753	4825	14556	14386	3582	0	59910

A. Mission Description and Budget Item Justification: This project funds technical development of candidate medical products for the advancement of combat casualty care; especially far forward on the battlefield with first responders, combat life savers, and field medics. This funds Phase 1 and 2 human clinical trials for safety and efficacy of devices unique to military operational requirements. These products will decrease mortality rates increase soldiers' morale and willingness to place themselves in danger. Additionally, several products will reduce the medical organizational sustainment footprint through smaller the weight and cube and equipment independence from supporting materials. Priority is given to those products that provide the greatest clinical benefit balanced with the technical and financial risks.

Accomplishments/Planned Program	FY 2004	FY 2005	FY 2006	FY 2007
Hemostatic Dressing (HD): In FY04, closed out contract with American Red Cross (ARC) due to ARC financial problems and subsequent program unaffordability. In FY05, develop cooperative agreement with new development partner.	285	3490	0	0
Demonstrate, evaluate, and continue to develop medical evacuation systems: Special Medical Emergency Evacuation Device (SMEED): In FY04, attained a restricted Army Air Worthiness Release (AWR) for combat. Began computer-simulated structural analysis to attain unlimited AWR. Initiated development of power control and battery module. In FY05, complete design of power control and battery module. Attain Milestone C.	237	209	0	0

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)

February 2005

BUDGET ACTIVITY

4 - Advanced Component Development and Prototypes

PE NUMBER AND TITLE

0603□0□A - Medical Systems - Adv Dev

PROJECT

□36

Accomplishments/Planned Program (continued)

Conduct/Perform development, testing and Milestone reviews for field medical treatment and treatment aid devices:

(1) Ceramic Oxygen Generator (COG): In FY04, developed efficient and stable oxygen generator cells, and designed portable oxygen generator. In FY05, fabricate first portable oxygen generator prototype. In FY06, conduct user and technical testing. Conduct Milestone B. In FY07, develop engineering pre-production prototype and obtain FDA clearance.

(2) Ventilatory Assist Device (VAD): In FY04, integrated ventilator drive unit with the anesthesia vaporizer. Produced user-training materials. In FY05, conduct technical and user testing, and make any required modifications. Hold Milestone C review. Support the fielding process.

(3) One-Handed Tourniquet (OHT): In FY04, released request for information and solicited potential commercial off-the-shelf improved tourniquet candidates. Continued human factors evaluation and technical testing. In FY05, recommend commercial off the shelf procurement and fielding.

(4) Non-Contact Respiration Monitor (NCRM): In FY04, refined respiration sensor, miniaturized electronics, and developed advanced prototype with reduced weight and volume. In FY05, conduct user evaluation and establish requirement. In FY06, conduct Milestone B. Develop engineering pre-production prototype. In FY07, conduct technical and user testing and evaluations.

(5) Rotary Valve Pressure Swing Adsorption Oxygen Generator (RVPSAOG): In FY04, designed feed air compressor, and developed prototype lightweight portable oxygen generator. In FY05, reduce oxygen generator weight and size. Conduct Milestone B review. In FY06, develop engineering pre-production prototype. Conduct technical and user testing and evaluation. Conduct Milestone C review. In FY07, initiate low rate production.

(6) Battery Powered IV Fluid Warmer: In FY06, begin concept development. In FY07, conduct user and technical testing.

FY 2004 FY 2005 FY 2006 FY 2007

3376 3626 3694 3753

Small Business Innovative Research/Small Business Technology Transfer Programs

71 0 0 0

Totals

3969 7325 3694 3753

B. Other Program Funding Summary: Not applicable for this item.

C. Acquisition Strategy:Evaluate commercially developed materiel in government-managed tests for hardening or other modification.

ARMY RDT&E COST ANALYSIS(R3)									February 2005			
BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes					PE NUMBER AND TITLE 0603□0□A - Medical Systems - Adv Dev					PROJECT □36		
I. Product Development	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
a . No other contract exceeds \$1M			11824	0		0		0		0	11824	0
Subtotal:			11824	0		0		0		0	11824	0
II. Support Cost	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
Subtotal:			0	0		0		0		0	0	0
Remarks: No product/contract costs greater than \$1M individually.												

ARMY RDT&E COST ANALYSIS(R3)									February 2005			
BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes					PE NUMBER AND TITLE 060300A - Medical Systems - Adv Dev					PROJECT 36		
III. Test and Evaluation	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
			0	0		0		0		0	0	0
Subtotal:												
Remarks: No product/contract costs greater than \$1M individually.												
IV. Management Services	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
a . No product/contract costs greater than \$M individually.			10660	7325		3694		3753		0	25432	0
Subtotal:			10660	7325		3694		3753		0	25432	0
Project Total Cost:			22484	7325		3694		3753		0	37256	0

Schedule Profile (R4 Exhibit)	February 2005
--------------------------------------	----------------------

4 - Advanced Component Development and Prototypes

06030A - Medical Systems - Adv Dev

36

Event Name	FY 04				FY 05				FY 06				FY 07				FY 08				FY 09				FY 10				FY 11			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4				
(1) SMEED					MS C 1																											
(2) Ceramic Oxygen Generator, (3) Ceramic Oxygen Generator, (4) Ceramic Oxygen Generator					MS A 2				MS B 3				MS C 4																			
(5) Ventalitory Assist Device					MS C 5																											
(6) One-handed Tourniquet					MS C 6																											
(7) Non-contact Respiration Monitor, (8) Non-contact Respiration Monitor									MS B 7								MS C 8															
(9) Rotary Valve Pressure Oxygen Generator, (10) Rotary Valve Pressure Oxygen Generator					MS B 9				MS C 10																							
(11) Battery-powered IV Fluid Warmer, (12) Battery-powered IV Fluid Warmer									MS A 11				MS B 12																			
(13) Battery-powered IV Fluid Warmer																					MS C 13											

Schedule Detail (R4a Exhibit)							February 2005	
BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes				PE NUMBER AND TITLE 060300A - Medical Systems - Adv Dev			PROJECT 36	
<u>Schedule Detail</u>	FY 2004	FY 2005	FY 2006	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011
SMEED (MS C)		4Q						
Ceramic Oxygen Generator Systems (MS A, MS B, MS C)		3Q	4Q		1Q			
Ventilatory Assist Device (MS C)		2Q						
One-Handed Tourniquet (MS, C)		3Q						
Non-contact Respiration Monitor (MS B, MS C)			4Q		4Q			
Rotary Valve Pressure Swing Oxygen Generator (MSB, MS C)		3Q	3Q					
Battery-powered IV Fluid Warmer (MS A, MS B, MS C)			2Q		1Q		1Q	

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)

February 2005

BUDGET ACTIVITY

4 - Advanced Component Development and Prototypes

PE NUMBER AND TITLE

0603□0□A - Medical Systems - Adv Dev

PROJECT

□3□

COST (In Thousands)	FY 2004 Actual	FY 2005 Estimate	FY 2006 Estimate	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	Cost to Complete	Total Cost
837 SOLDIER SYS PROT-AD	1063	712	951	2534	1934	1866	1780	1778	0	13467

A. Mission Description and Budget Item Justification: This project supports the conceptual and technical development of preventive medicine materiel including devices and medicines in order to provide protection, sustainment, and enhancement of the physical and psychological capabilities of soldiers across all conditions of combat. Focus is on the reduction of personnel losses due to preventable disease and non-battle injuries through the development of environmental and physiological performance monitors and other preventive medicine countermeasures.

Accomplishments/Planned Program

In FY04, a field trial of the Hepatitis E Vaccine was completed in Nepal. In FY05, conduct stability studies with commercial partner on the three lots of Leishmania tropica skin tests, and manufacture skin tests for the Phase 2 safety and immunological genetics studies to be conducted in Turkey. In FY06, continue stability testing of original three lots, start stability testing on the skin tests made for the Phase 3 study, and begin a Phase 2 field trial with the Leishmania tropica skin test. In FY07, review and evaluate Phase 2 field trial results, and continue stability testing on skin tests being prepared for Phase 3 trials. Prepare to conduct Phase 3 field trials.

	FY 2004	FY 2005	FY 2006	FY 2007
	1032	712	951	2534
Small Business Innovative Research/Small Business Technology Transfer Programs	31	0	0	0
Totals	1063	712	951	2534

B. Other Program Funding Summary: Not applicable for this item.

C. Acquisition Strategy: Test and evaluate materiel in government-managed trials to meet fielding requirements.

ARMY RDT&E COST ANALYSIS(R3)									February 2005			
BUDGET ACTIVITY					PE NUMBER AND TITLE					PROJECT		
4 - Advanced Component Development and Prototypes					060300A - Medical Systems - Adv Dev					03		
I. Product Development	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
a . No product/contract costs greater than \$1M individually			1447	342		456		1217		Continue	3462	0
Subtotal:			1447	342		456		1217		Continue	3462	0
II. Support Cost	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
a . No product/contract costs greater than \$1M individually			79	23		29		75		Continue	206	0
Subtotal:			79	23		29		75		Continue	206	0

ARMY RDT&E COST ANALYSIS(R3)									February 2005				
BUDGET ACTIVITY					PE NUMBER AND TITLE					PROJECT			
4 - Advanced Component Development and Prototypes					060300A - Medical Systems - Adv Dev					03			
III. Test and Evaluation	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract	
a . No product/contract costs greater than \$1M individually		Research and development; stability and potency testing	356	127		172		456		Continue	1111	0	
Subtotal:			356	127		172		456		Continue	1111	0	
IV. Management Services	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract	
a . No product/contract costs greater than \$1M individually			885	220		294		786		Continue	2185	0	
Subtotal:			885	220		294		786		Continue	2185	0	
Project Total Cost:			2767	712		951		2534		Continue	6964	0	

Schedule Profile (R4 Exhibit)																								February 2005											
BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes												PE NUMBER AND TITLE 060300A - Medical Systems - Adv Dev																				PROJECT 030			
Event Name	FY 04				FY 05				FY 06				FY 07				FY 08				FY 09				FY 10				FY 11						
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4							
(1) MS B					Leishmania Skin Test				1																										

Schedule Detail (R4a Exhibit)							February 2005	
BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes				PE NUMBER AND TITLE 0603□0□A - Medical Systems - Adv Dev				PROJECT □3□

<u>Schedule Detail</u>	FY 2004	FY 2005	FY 2006	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011
Leishmania Skin Test			4Q					